Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Colorcon
Express Scripts
Mallinckrodt
Merck

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for PF-05175157

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug PF-05175157: Patents, clinical trial progress, indications

PF-05175157 is an investigational drug.

There have been 13 clinical trials for PF-05175157. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2014.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Overweight. The leading clinical trial sponsors are Pfizer and [disabled in preview].

There are four US patents protecting this investigational drug and forty-four international patents.

Recent Clinical Trials for PF-05175157
TitleSponsorPhase
Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne VulgarisPfizerPhase 2
A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking MetforminPfizerPhase 2
A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking MetforminPfizerPhase 2

See all PF-05175157 clinical trials

Clinical Trial Summary for PF-05175157

Top disease conditions for PF-05175157
Top clinical trial sponsors for PF-05175157

See all PF-05175157 clinical trials

US Patents for PF-05175157

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-05175157   Start Trial N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors Pfizer Inc. (New York, NY)   Start Trial
PF-05175157   Start Trial N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors Pfizer Inc. (New York, NY)   Start Trial
PF-05175157   Start Trial N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors Pfizer Inc. (New York, NY)   Start Trial
PF-05175157   Start Trial N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors Pfizer Inc. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-05175157

Drugname Country Document Number Estimated Expiration Related US Patent
PF-05175157 African Regional IP Organization (ARIPO) 3283 2029-11-10   Start Trial
PF-05175157 Argentina 078944 2029-11-10   Start Trial
PF-05175157 Australia 2010317501 2029-11-10   Start Trial
PF-05175157 Brazil 112012011072 2029-11-10   Start Trial
PF-05175157 Canada 2778886 2029-11-10   Start Trial
PF-05175157 China 102695708 2029-11-10   Start Trial
PF-05175157 Colombia 6541569 2029-11-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Johnson and Johnson
McKinsey
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.